Emergency Contraceptives Market: By Drug Class pills, Antiprogestin pills, Ulipristal acetate pills), By Distribution Channel and Geography 

Emergency Contraceptives Market Size, Share, Growth, Trends, and Global Industry Analysis: By Drug Class (Combined estrogen and progestin pills, Progestin-only (as Levonorgestrel) pills, Antiprogestin (as mifepristone) pills, Ulipristal acetate pills), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Others) and Region 

Emergency Contraceptives Market size was valued at US$ 30.2 billion in 2023 and is poised to grow at a significant CAGR of 8.2% from 2024-2030. Emergency Contraceptives Market, provides emergency contraception methods are intended to prevent unwanted pregnancies after sexual intercourse.The commonly used emergency contraceptives are pills and copper-bearing intrauterine devices.Within emergency contraceptive pills are available in 3 compositions namely, combined estrogen and progestin pills, progestin-only (as Levonorgestrel) pills, and antiprogestin (as mifepristone) pills. Emergency contraceptives are different from normal contraceptives. The mechanism of action of the emergency contraceptive methods is delaying or preventing ovulation or fertilization, which is necessary during pregnancy. Both the methods are effective only before the pregnancy testing implanted.

These procedures are ineffective after the implantation occurred. Furthermore, low cost of the products, rise in the adoption of modern emergency contraceptives in developing countries, ease of administration of emergency contraceptive pills, and high effectiveness and convenience in emergency contraceptive devices might boost the global emergency contraceptives pills market. However, adverse effects like nausea, headache associated with the emergency contraceptive pills, lack of skilled professionals for the insertion of intrauterine devices, and product failures in some cases might hamper the market. Market players investing heavily to manufacture emergency contraceptives to increase their share in the market. Launching of new products, collaborations, acquisitions and mergers, approvals as over the counter (OTC) product from various drug regulators such as U.S. Food and Drug Administration, and research and developments are some key strategies followed by various pharmaceutical companies to increase the share in the global emergency contraceptives market.

Emergency Contraceptives Market Key Developments:

  • In August 2010, U.S. Food and Drug Administration approved the Ella (Ulipristal acetate pills) as emergency contraceptive pills which are developed by HRA pharmaceuticals.
  • In February 2011, Teva Pharmaceuticals received an approval from the FDA for requesting non-prescription status for Plan B One-Step for women under the age of 17.

Global Emergency Contraceptives Market Summary

Study Period

2024-2030

Base Year

2023

CAGR

8.2%

Largest Market

North America

Fastest Growing Market

Europe

Emergency Contraceptives Market Dynamics

The global emergency contraceptives market is expected to grow at an unprecedented CAGR due to the increase in the global female population. Increase in the public awareness in making right decisions about their sexual and reproductive health, technological advancements and an increase in the development of effective female contraceptive drugs and devices, and availability of products in the market might fuel the market.

Global Emergency Contraceptives Market Segmentation Analysis

Report Benchmarks

Details

Report Study Period

2024-2030

Market Size in 2023

US$ 30.2 billion

Market CAGR

8.2%

By Drug Class

  • Combined estrogen and progestin pills
  • Progestin-only (as Levonorgestrel) pills
  • Antiprogestin (as mifepristone) pills
  • Ulipristal acetate pills

By Distribution Channel

  • Hospital pharmacies
  • Retail pharmacies
  • Online pharmacies
  • Others

By Region

  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East and Africa

Key Features of the Report

  • The report provides granular level information about the market size, regional market share, historic market (2019-2023), and forecast (2024-2030)
  • The report covers in-detail insights about the competitor's overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments, and start-up details that are actively working in the market
  • The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario

Download Free Sample Report

Frequently Asked Questions

The Emergency contraceptives market size was valued at US$ 30.2 billion in 2023

The key segments covered in the Emergency contraceptives market are technology, components, application, and end-users.

The Emergency contraceptives market key players are Gynetics NV (Belgium), Teva Pharmaceutical Industries Ltd. (Israel), Uniprix group (Canada), Gavis Pharmaceuticals LLC, (A Lupin Group Company) (U.S.), HRA Pharma (Paris), Mankind Pharma (India)

Author image

Author

Muni Kumar Meravath

Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthc.....

1. Executive Summary
2. Global Emergency Contraceptives Market Introduction 
2.1.Global Emergency Contraceptives Market  - Taxonomy
2.2.Global Emergency Contraceptives Market  - Definitions
2.2.1.Drug Class
2.2.2.Distribution Channel
2.2.3.Region
3. Global Emergency Contraceptives Market Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Product Landscape
3.6. New Product Launches
3.7. Impact of COVID 19 on Market
4. Global Emergency Contraceptives Market Analysis, 2019 - 2023 and Forecast 2024 - 2030
4.1.  Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
4.2.  Year-Over-Year (Y-o-Y) Growth Analysis (%) 
4.3.  Market Opportunity Analysis 
5. Global Emergency Contraceptives Market  By Drug Class, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
5.1. Combined estrogen and progestin pills
5.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.1.3. Market Opportunity Analysis 
5.2. Progestin-only (as Levonorgestrel) pills
5.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.2.3. Market Opportunity Analysis 
5.3. Antiprogestin (as mifepristone) pills
5.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.3.3. Market Opportunity Analysis 
5.4. Ulipristal acetate pills
5.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
5.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.4.3. Market Opportunity Analysis 
6. Global Emergency Contraceptives Market  By Distribution Channel, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
6.1. Hospital pharmacies
6.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.1.3. Market Opportunity Analysis 
6.2. Retail pharmacies
6.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.2.3. Market Opportunity Analysis 
6.3. Online pharmacies
6.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.3.3. Market Opportunity Analysis 
6.4. Others
6.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
6.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.4.3. Market Opportunity Analysis 
7. Global Emergency Contraceptives Market  By Region, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
7.1. North America
7.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.1.3. Market Opportunity Analysis 
7.2. Europe
7.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.2.3. Market Opportunity Analysis 
7.3. Asia Pacific (APAC)
7.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.3.3. Market Opportunity Analysis 
7.4. Middle East and Africa (MEA)
7.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
7.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.4.3. Market Opportunity Analysis 
7.5. Latin America
7.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
7.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.5.3. Market Opportunity Analysis 
8. North America Emergency Contraceptives Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
8.1. Drug Class Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
8.1.1.Combined estrogen and progestin pills
8.1.2.Progestin-only (as Levonorgestrel) pills
8.1.3.Antiprogestin (as mifepristone) pills
8.1.4.Ulipristal acetate pills
8.2.  Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
8.2.1.Hospital pharmacies
8.2.2.Retail pharmacies
8.2.3.Online pharmacies
8.2.4.Others
8.3.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
8.3.1.United States of America (USA)
8.3.2.Canada
9. Europe Emergency Contraceptives Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
9.1. Drug Class Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.1.1.Combined estrogen and progestin pills
9.1.2.Progestin-only (as Levonorgestrel) pills
9.1.3.Antiprogestin (as mifepristone) pills
9.1.4.Ulipristal acetate pills
9.2.  Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.2.1.Hospital pharmacies
9.2.2.Retail pharmacies
9.2.3.Online pharmacies
9.2.4.Others
9.3.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.3.1.Germany
9.3.2.France
9.3.3.Italy
9.3.4.United Kingdom (UK)
9.3.5.Spain
9.3.6.Rest of EU
10. Asia Pacific (APAC) Emergency Contraceptives Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
10.1. Drug Class Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.1.1.Combined estrogen and progestin pills
10.1.2.Progestin-only (as Levonorgestrel) pills
10.1.3.Antiprogestin (as mifepristone) pills
10.1.4.Ulipristal acetate pills
10.2.  Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.2.1.Hospital pharmacies
10.2.2.Retail pharmacies
10.2.3.Online pharmacies
10.2.4.Others
10.3.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.3.1.China
10.3.2.India
10.3.3.Australia and New Zealand (ANZ)
10.3.4.Japan
10.3.5.Rest of APAC
11. Middle East and Africa (MEA) Emergency Contraceptives Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
11.1. Drug Class Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.1.1.Combined estrogen and progestin pills
11.1.2.Progestin-only (as Levonorgestrel) pills
11.1.3.Antiprogestin (as mifepristone) pills
11.1.4.Ulipristal acetate pills
11.2.  Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.2.1.Hospital pharmacies
11.2.2.Retail pharmacies
11.2.3.Online pharmacies
11.2.4.Others
11.3.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.3.1.GCC Countries
11.3.2.South Africa
11.3.3.Rest of MEA
12. Latin America Emergency Contraceptives Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
12.1. Drug Class Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.1.1.Combined estrogen and progestin pills
12.1.2.Progestin-only (as Levonorgestrel) pills
12.1.3.Antiprogestin (as mifepristone) pills
12.1.4.Ulipristal acetate pills
12.2.  Distribution Channel Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.2.1.Hospital pharmacies
12.2.2.Retail pharmacies
12.2.3.Online pharmacies
12.2.4.Others
12.3.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.3.1.Brazil
12.3.2.Mexico
12.3.3.Rest of LA
13. Competition Landscape
13.1.  Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) 
13.2.1.Gynetics NV (Belgium)
13.2.2.Teva Pharmaceutical Industries Ltd. (Israel)
13.2.3.Uniprix group (Canada)
13.2.4.Gavis Pharmaceuticals LLC, (A Lupin Group Company) (U.S)
13.2.5.HRA Pharma (Paris)
13.2.6.Mankind Pharma (India)
14. Research Methodology 
15. Appendix and Abbreviations 

Key Market Players

  • Gynetics NV (Belgium)
  • Teva Pharmaceutical Industries Ltd. (Israel)
  • Uniprix group (Canada)
  • Gavis Pharmaceuticals LLC, (A Lupin Group Company) (U.S)
  • HRA Pharma (Paris)
  • Mankind Pharma (India)

Related Industry Reports